Home > Analytics > SHUKRA PHARMACEUTICALS

SHUKRA PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 524632     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward
Pledged Shares : NA
Jul 16,2024
Price(EOD): ₹ 87.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 384.13 Cr
Value of ₹ 1 Lac invested in SHUKRA PHARMACEUTICALS
on Jul 17,2019 (price: ₹ 2.60)

₹ 1 L

₹ 33.78 L

1W : -7.7% 1M : -24.6% 1Y : 103.2%
COMMUNITY POLL
for SHUKRA PHARMACEUTICALS
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
SHUKRA PHARMACEUTICALS -7.7% -24.6% 103.2%
SUN PHARMACEUTICAL INDUSTRIES -1.1% 4.2% 47.1%
CIPLA -0.1% -3.5% 48.3%
DR REDDYS LABORATORIES 0.8% 9.2% 30.9%
ZYDUS LIFESCIENCES 0.4% 6.9% 100.2%
DIVIS LABORATORIES -1.6% -0.5% 25.9%
MANKIND PHARMA -1.6% -5.6% 14.4%
TORRENT PHARMACEUTICALS 0.7% 3.2% 53%
LUPIN 1% 15% 94.9%

FUNDAMENTAL ANALYSIS OF SHUKRA PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Mar2024, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SHUKRA PHARMACEUTICALS

 
Valuation Score
[As on : Jul 16,2024 ]

Ratio Standalone
P/E
P/B
P/S
20.72
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 18.54 Cr
[Latest Qtr - Mar2024 - Standalone Results ]

15.18
P/B Calculated based on Book Value of Rs 25.30 Cr
[Latest Year - Mar2023 - Standalone Results ]

5.15
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2024 - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 10% undervalued companies ! Discover More →

FAIR VALUE OF SHUKRA PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
753%
115%
345%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SHUKRA PHARMACEUTICALS



SHUKRA PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SHUKRA PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.2
0.21
0.63
0.35
-
-
-
-
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SHUKRA PHARMACEUTICALS

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SHUKRA PHARMACEUTICALS

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-42.39%
-53.54%
-45.17%
-57.69%
-76.47%
21.38%
31.72%
0.2%
QtrlyTrend
-2
Latest Qtr: Mar2024
Quarterly Result Analysis →


SHUKRA PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about SHUKRA PHARMACEUTICALS


Is SHUKRA PHARMACEUTICALS good for long term investment?

As on Jul 16,2024, the Fundamentals of SHUKRA PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SHUKRA PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SHUKRA PHARMACEUTICALS UnderValued or OverValued?

As on Jul 16,2024, SHUKRA PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SHUKRA PHARMACEUTICALS ?

As on Jul 16,2024, the Intrinsic Value of SHUKRA PHARMACEUTICALS is Rs. 19.72 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 10.28
Fair Value [Median EV / Sales Model] : Rs. 40.72
Fair Value [Median Price / Sales Model] : Rs. 19.72
Estimated Median Fair Value of SHUKRA PHARMACEUTICALS : Rs. 19.72

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SHUKRA PHARMACEUTICALS trading at a Premium or Discount?

As on Jul 16,2024, SHUKRA PHARMACEUTICALS is trading at a Premium of 345% based on the estimates of Median Intrinsic Value!